STOCK TITAN
  1. Home
  2. News
  3. ALKS

Alkermes Proudly Announces Release of 2023 Corporate Responsibility Report

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Alkermes proudly announces release of 2023 Corporate Responsibility Report
Positive
  • Alkermes releases Corporate Responsibility Report detailing progress in 2022
Negative
  • None.

NORTHAMPTON, MA / ACCESSWIRE / October 11, 2023 / Alkermes

Corporate responsibility is foundational to our business. We are proud to release our latest Corporate Responsibility Report, which details our progress in 2022 related to environmental sustainability, diversity, inclusion and belonging and ethical governance. Read the full report: https://www.alkermes.com/responsibility#csr

View additional multimedia and more ESG storytelling from Alkermes on 3blmedia.com.

Contact Info:
Spokesperson: Alkermes
Website: https://www.3blmedia.com/profiles/alkermes
Email: info@3blmedia.com

SOURCE: Alkermes



View source version on accesswire.com:
https://www.accesswire.com/792022/alkermes-proudly-announces-release-of-2023-corporate-responsibility-report

The news is about Alkermes releasing their 2023 Corporate Responsibility Report.

The report details Alkermes' progress in 2022 related to environmental sustainability, diversity, inclusion and belonging, and ethical governance.

You can read the full report at https://www.alkermes.com/responsibility#csr.

No, there is no negative impact on the stock price.

No specific positive impact on stock price is mentioned in the news.

Alkermes' website is https://www.3blmedia.com/profiles/alkermes.

Alkermes' contact email is info@3blmedia.com.
Stock ALKS logo
Alkermes plc

NASDAQ:ALKS

ALKS Rankings

#1315 Ranked by Market Cap
#1668 Ranked by Stock Gains
N/A Ranked by Dividends

ALKS Latest News

Apr 24, 2024
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1
Apr 17, 2024
Alkermes to Report First Quarter Financial Results on May 1, 2024
Apr 9, 2024
Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia
Apr 8, 2024
Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society
Mar 7, 2024
Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors

ALKS Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing

About ALKS

alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (cns) diseases. the company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. headquartered in dublin, ireland, alkermes plc has an r&d center in waltham, massachusetts; a research and manufacturing facility in athlone, ireland; and a manufacturing facility in wilmington, ohio. for more information, please visit alkermes’ website at www.alkermes.com.